Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30552
Full metadata record
DC FieldValueLanguage
dc.contributor.authorShi, Yue-
dc.contributor.authorJi, Min-
dc.contributor.authorJiang, Yingying-
dc.contributor.authorYin, Rong-
dc.contributor.authorWang, Zihan-
dc.contributor.authorLi, Hang-
dc.contributor.authorWang, Shuaiyu-
dc.contributor.authorHe, Kang-
dc.contributor.authorMa, Yuxin-
dc.contributor.authorWang, Zhitong-
dc.contributor.authorLu, Jianwei-
dc.contributor.authorShi, Meiqi-
dc.contributor.authorShen, Bo-
dc.contributor.authorZhou, Guoren-
dc.contributor.authorLeong, Tracy L-
dc.contributor.authorWang, Xiaohua-
dc.contributor.authorChen, Cheng-
dc.contributor.authorFeng, Jifeng-
dc.date.accessioned2022-07-19T06:57:57Z-
dc.date.available2022-07-19T06:57:57Z-
dc.date.issued2022-06-
dc.identifier.citationTranslational lung cancer research 2022; 11(6): 1051-1068en
dc.identifier.issn2218-6751
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30552-
dc.description.abstractAnlotinib is a new multi-target tyrosine kinase inhibitor (TKI) and has been shown to have antitumor effects and synergistic antitumor effects with immunotherapy only in animal studies and in the 2nd-line treatment in small clinical trials. A real-world study with large sample to compare the efficacy and safety of anlotinib plus immune checkpoint inhibitors (ICIs) with ICIs alone in the multiline treatment of advanced non-small cell lung cancer (NSCLC) was urgently needed. The data of 535 advanced NSCLC patients were collected from January 1, 2018, to December 31, 2021. The patients were divided into 2 groups: (I) ICI monotherapy (230 patients); (II) ICI + anlotinib (305 patients). After propensity-score matching (PSM) to reduce the effects of biases and confounding variables, the progression-free survival time (PFS), occurrence of adverse events, disease control rate (DCR), and objective response rate (ORR) of the 2 groups were compared. The effects of clinical factors, including age, gender, gene mutations, tumor proportion score, metastases, and combined radiotherapy, were also analyzed. After PSM, the baseline clinical characteristics were well balanced and the 2 group had a good comparability. Patients in the ICI + anlotinib group had significantly longer median PFS in both the 2nd-line treatment (7.73 vs. 4.70 months; P=0.003) and 3rd-line treatment (5.90 vs. 3.37 months; P=0.020), but the difference lacked statistical significance in the 1st-line treatment (8.40 vs. 5.20 months; P=0.229). The overall median PFS of patients in the ICI + anlotinib group was also much longer than that of patients in the ICI monotherapy group (6.37 vs. 3.90 months; P<0.001). The ICI + anlotinib group also tended to have a higher DCR, a higher ORR, and a higher probability of severe adverse drug reactions during the treatment than the ICI monotherapy group, but the differences were not statistically significant. Combining ICI + anlotinib could improve the outcomes of patients with bone metastasis. Anlotinib + ICI therapy could have greater efficacy in the treatment of advanced NSCLC patients than ICI monotherapy. The probability of adverse events might increase in the combined treatment, but could be controlled.en
dc.language.isoeng
dc.subjectNon-small cell lung cancer (NSCLC)en
dc.subjectanlotiniben
dc.subjectcombined therapyen
dc.subjectimmunotherapyen
dc.titleA cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.en
dc.typeJournal Articleen_US
dc.identifier.journaltitleTranslational lung cancer researchen
dc.identifier.affiliationDepartment of Oncology, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China..en
dc.identifier.affiliationDepartment of Radiotherapy, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China..en
dc.identifier.affiliationDepartment of Thoracic Surgery, the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China..en
dc.identifier.affiliationSchool of Life Science, Nantong University, Nantong, China..en
dc.identifier.affiliationDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA..en
dc.identifier.affiliationUCL School of Pharmacy, University College London, London, UK..en
dc.identifier.affiliationDepartment of Radiotherapy, Nanjing Medical University, Nanjing, China..en
dc.identifier.affiliationRespiratory and Sleep Medicineen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35832459/en
dc.identifier.doi10.21037/tlcr-22-350en
dc.type.contentTexten_US
dc.identifier.pubmedid35832459
local.name.researcherLeong, Tracy L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptInstitute for Breathing and Sleep-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.